Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? results of the start (self-titration with apidra to reach target) study a randomized noninferiority trial

Diabetes Care

Volumn 37, Issue 3, 2014, Pages 604-610

  Harris, Stewart B ^a   Yale, Jean Francois ^b   Berard, Lori ^c   Stewart, John ^d   Abbaszadeh, Babak ^d   Webster Bogaert, Susan ^a   Gerstein, Hertzel C ^e  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

^d Medical and Regulatory Affairs   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN GLULISINE; ANTIDIABETIC AGENT; GLARGINE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN; LONG ACTING INSULIN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE UTILIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; JOB SATISFACTION; MAJOR CLINICAL STUDY; MALE; MEAL; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN ATTITUDE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF CARE; TREATMENT OUTCOME; TREATMENT PLANNING; AGED; ALGORITHM; ANALOGS AND DERIVATIVES; BLOOD; BLOOD GLUCOSE MONITORING; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG SELF ADMINISTRATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; ALGORITHMS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; SELF ADMINISTRATION; TREATMENT OUTCOME;

EID: 84896739454     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1636     Document Type: Article

References (34)

1. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-336
2. Jaakkimainen L, Baiju RS, Kopp A. Sources of physician care for people with diabetes. In Diabetes in Ontario: An ICES Practice Atlas. Hux J, Booth G, Slaughter P, Laupacis A, Eds. Toronto, ON, Canada, Institute for Clinical Evaluative Sciences, 2003, p. 181-191
3. Harris SB, Kapor J, Lank CN, Willan AR, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician 2010;56:e418-e424
4. Yki-Jarvinen H. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue. Eur J Clin Invest 2004;34: 410-416
5. Chapman TM, Noble S, Goa KL. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2002;62:1945-1981
6. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:736-742
7. Davies M, Storms F, Shutler S, Bianchi-BiscayM, Gomis R; ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282-1288
8. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086
9. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-451
10. Harris S, Yale JF, Dempsey E, Gerstein H. Can family physicians help patients initiate basal insulin therapy successfully? Randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. Can Fam Physician 2008;54:550-558
11. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 2006;32(Suppl.):9S-18S
12. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011;34:2508-2514
13. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003;26:881-885
14. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-269
15. Monnier L, Colette C, Owens D. Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts. Diabetes Technol Ther 2011;13 (Suppl. 1):S25-S32
16. Peter R, Dunseath G, Luzio SD, Chudleigh R, Choudhury SR, Owens DR. Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA(1c) in subjects with type 2 diabetes. Diabet Med 2009;26: 974-980
17. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007;77:280-285
18. Ceriello A. The glucose triad and its role in comprehensive glycaemic control: current status, future management. Int J Clin Pract 2010;64:1705-1711
19. Pearson J, Powers MA. Systematically initiating insulin: the staged diabetes management approach. Diabetes Educ 2006;32(Suppl.):19S-28S
20. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35: 1364-1379
21. Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract 2011;17: 395-403
22. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA; Orals Plus Apidra and LANTUS (OPAL) study group. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two singledose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008;10:1178-1185
23. Holman RR, Farmer AJ, Davies MJ, et al.; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-1747
24. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enoughdwhat next? Diabetes Metab Res Rev 2007;23:257-264
25. Bradley C, Plowright R, Stewart J, Valentine J, Witthaus E. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Health Qual Life Outcomes 2007;5:57
26. Selam J, Meneghini L. Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial. Adv Ther 2009;26:194-207
27. Peyrot M, Rubin RR, Lauritzen T, et al.; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the crossnational Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28:2673-2679
28. Davis S, Renda SM. Psychological insulin resistance: overcoming barriers to starting insulin therapy. Diabetes Educ 2006;32 (Suppl. 4):146S-152S
29. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl 2009:6-10
30. Peyrot M. Psychological insulin resistance: overcoming barriers to insulin therapy. Practical Diabetology 2004;23:6-12
31. Anderson RM, Funnell MM. Patient empowerment: myths and misconceptions. Patient Educ Couns 2010;79:277-282
32. Funnell MM, Anderson RM. Empowerment and self-management of diabetes. Clin Diabetes 2004;22:123-127
33. White RD. Patient empowerment and optimal glycemic control. Curr Med Res Opin 2012;28:979-989
34. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16.Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. prospective diabetes study group. Diabetes 1995;44: 1249-1258